Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Estee Lauder Companies Inc (EL) Price & Performance

CVS Health CorpTrade
Estee Lauder Companies IncTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Estee Lauder Companies Inc — how do they compare? CVS Health Corp trades at $93.54 (market cap $122.36B), while Estee Lauder Companies Inc trades at $87.54 (market cap $31.54B). The key difference: CVS Health Corp is far larger — about 3.9× Estee Lauder Companies Inc's market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.

CVSEL
Market Cap
$122.36B$31.54B
Sector
HealthConsumer Staples
52-Week High
$110.60$119.61
52-Week Low
$64.88$67.23
Enterprise Value
$184.71B$37.72B
Dividend Yield
2.78%1.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

Estee Lauder Companies Inc

Estée Lauder (EL) trades at $88.35, up 3.35% with a bullish technical signal and recent earnings beats. The stock shows strong institutional interest with Bank of America increasing its stake by 950.9% in Q1 2026. Despite negative net income margins, the company maintains a robust gross margin of 74.71% and has upcoming Q2 2026 earnings expected at $0.3197 per share. Recent corporate developments include a new fragrance launch and executive appointments.

The outlook remains cautiously optimistic with a consensus price target of $91.67 offering 3.8% upside potential. Key risks include declining revenue trends and negative profitability, while opportunities lie in product innovation and digital engagement. The stock faces resistance near $90-$93 levels with support at $86.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS

About Estee Lauder Companies Inc

Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.

Read more on EL